| 17.2 -0.82 (-4.55%) | 01-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 22.22 | 1-year : | 24.16 |
| Resists | First : | 19.03 | Second : | 20.69 |
| Pivot price | 18.18 |
|||
| Supports | First : | 16.35 | Second : | 13.6 |
| MAs | MA(5) : | 18.13 |
MA(20) : | 18.22  |
| MA(100) : | 17.92 |
MA(250) : | 13.72 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.2 |
D(3) : | 36.5 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 22.69 | Low : | 6.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PLSE ] has closed above bottom band by 12.1%. Bollinger Bands are 46.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.32 - 18.42 | 18.42 - 18.53 |
| Low: | 16.91 - 17.02 | 17.02 - 17.14 |
| Close: | 16.99 - 17.18 | 17.18 - 17.39 |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Mon, 13 Jan 2025
Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium - Business Wire
Mon, 13 Jan 2025
Pulse Biosciences' Breakthrough nsPFA Cardiac Catheter to Headline AF Symposium 2025 - StockTitan
Sat, 11 Jan 2025
Pulse Biosciences announces CEO appointment - MSN
Fri, 10 Jan 2025
Pulse Biosciences Names Boston Scientific Veteran LaViolette as CEO, Advances Cardiac Tech Pipeline - StockTitan
Fri, 10 Jan 2025
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer - Business Wire
Fri, 03 Jan 2025
Pulse Biosciences to Present Nano-PFA Technology at J.P. Morgan Healthcare Conference 2025 - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 62 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 80.8 (%) |
| Held by Institutions | 9.3 (%) |
| Shares Short | 2,170 (K) |
| Shares Short P.Month | 2,080 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.2 % |
| Return on Equity (ttm) | -70.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -20.73 |
| PEG Ratio | 0 |
| Price to Book value | 13.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -31.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|